D
espite advances in cardiac care including prompt reperfusion therapy, acute myocardial infarction (AMI) remains the most common cause of cardiovascular morbidity and mortality. 1, 2 Cell therapy is being investigated as a therapeutic strategy for AMI; however, results have been inconsistent as most clinical studies evaluating autologous cell therapy in patients after AMI have reported limited improvement in cardiac function. [3] [4] [5] [6] [7] Therefore, it is important to elucidate the factors that influence the efficacy of cell therapy in AMI because a better understanding may improve treatment results.
function was markedly impaired. 8 Also, there was a significant association between improved cardiac function after autologous BMC injection and bone marrow (BM)-derived vasculogenic colony-forming capacity and percentages of BM-derived stem/ progenitor (CD34 + ), endothelial (CD31 + ), and inflammatory/ monocytic (CD11b + ) cells. 9, 10 Although various cell types have been implicated, the potential of other factors (eg, proinflammatory cytokines, angiogenic factors, and sympathetic nervous system) 8, 11 to influence BM and peripheral blood (PB) cell composition and function have not been explored. Therefore, we hypothesized that the angiogenic and inflammatory response after AMI may negatively affect BMC contribution to the repair of damaged myocardium. Although it is known that AMI increases the number and activation state of inflammatory cells in circulation, heart, 12 and spleen, 5, 13 only one preclinical report supported our hypothesis, and patient data were lacking.
14 Thus, using banked specimens and clinical trial data from the CCTRN (Cardiovascular Cell Therapy Research Network) LateTIME study; we measured circulating cytokines and examined their association with BM function after AMI.
Methods

Study Population
Participants in the CCTRN Late-TIME study provided additional written consent to donate BM and PB for further analyses. 3 The Institutional Review Boards of the CCTRN clinical trial sites approved the clinical study, and the University of Florida Institutional Review Board approved this experimental study. Participants who experienced a large AMI (left ventricular [LV] ejection fraction [LVEF] <45% despite successful reperfusion) within the previous 14 to 21 days were eligible. A total of 87 patients with AMI provided BM and PB samples. Samples were shipped to the CCTRN Biorepository Core Laboratory. Plasma cytokine measurements, cell phenotyping, and cell function assays were performed on PB and BM samples. 15 Echocardiogram and cardiac magnetic resonance imaging studies were performed within 24 hours of the BM aspiration and repeated 6 months after BMC injection as described in detail elsewhere. 3, 16 
PB Cytokine Measurements
Cytokines from PB plasma were quantified using bead array technique (Bio-Plex, Bio-Rad Laboratories, Hercules, CA). Analytes included angiogenic or arteriogenic growth factors (basic fibroblast growth factor, platelet-derived growth factor BB glycoprotein [PDGF-BB], vascular endothelial growth factor, and stromal cellderived factor-1α), proinflammatory cytokines (eotaxin, granulocyte colony-stimulating factor [CSF] , granulocyte-macrophage CSF, interferon-γ, interleukin-1α [IL-1α], IL-1β, IL-2, IL-6, IL-7, IL-8, IL-9, IL-12, IL-15, IL-17, tumor necrosis factor-α, monocyte chemoattractant protein-1, and chemokine (C-C motif) ligand 5), and anti-inflammatory cytokines (IL-1 receptor antagonist [IL-1RA], IL-4, IL-5, IL-10, and IL-13). The assay was performed according to the manufacturer instructions. Patient samples and standards were assayed in duplicate. Cytokine measurements that were below the lower limit of detection (LOD), based on kit validation studies, were assigned the lowest rank or categorized in a low group. 
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Novelty and Significance
What Is Known?
• Bone marrow (BM) contains stem and progenitor cells capable of regenerating blood vessels in response to ischemia and inflammation.
• Experimental studies showed BM cell (BMC) therapy improved left ventricular (LV) function in animal models of acute myocardial infarction (AMI). However, only minimal LV function improvement has been reported after BMC therapy in AMI patients.
• While experimental AMI models have implicated cytokine-related impairment of BM cell regeneration, such a response has yet to be studied in humans.
What New Information Dose This Article Contribute?
• Patients with higher peripheral blood (PB) levels of IL-6 two to three weeks after AMI had impaired BM vasculogenic capacity.
• Patients with higher PB levels of platelet-derived growth factor BB protein (PDGF-BB) two to three weeks after AMI had improved BM vasculogenic capacity.
• IL-6 and IL-1β impaired BM vasculogenic capacity, which could be reversed by blocking IL-6R and IL-1R, respectively.
Bone marrow contains cells capable of regenerating the heart after acute myocardial infarction in experimental models. However, in BM cell therapy clinical trials, human patients have shown minimal functional improvement. Experimental evidence suggested that inflammatory cytokines may impair the cardiac repair capacity of BM cells. Here, we examined the PB cytokine levels from a large number of patients two to three weeks after acute MI. We report significant associations between cytokine levels and bone marrow function. Our study identified IL-6, IL-1β and PDGF-BB as important cytokines that may regulate autologous BM cell repair of ischemic heart disease in patients. The impairment of IL-6 and IL-1 β can be reversed by blocking IL-6R and IL-1R, respectively. Our study provides a mechanistic understanding of the mixed results seen with autologous BM cell clinical trials and suggests methods of improving this application.
Bone Marrow and PB Mononuclear Progenitor Colony Assays
BM and PB mononuclear cell function were evaluated by standardized endothelial colony-forming cell (ECFC) assay, colony-forming unit-endothelial colony assay, and multipotent mesenchymal stromal cell (MSC) colony assay, as previously described. 8, 15 Colony-forming unit-endothelial colony formations were enumerated every day for 14 days. ECFC and MSC colonies were enumerated every week for 4 weeks. The assays were performed in triplicate. The maximal number of colonies per plate was used for analyses.
In Vitro Cytokine Treatment of Healthy Donor BMCs
To evaluate the direct effect of exogenous cytokines on BM endothelial colony outgrowth (ECFC assay), 5 million BMC each from 3 healthy donors were plated in endothelial growth media-2 media on fibronectin dishes. The cells were incubated at 37°C in a fully humidified atmosphere with 5% CO 2 for 24 hours. The adherent cells were trypsinized and removed from the fibronectin dishes and then plated in 6-well dishes in the amount of 1 million cells/well. Then the cells were cultured separately in the presence of increasing concentrations of IL-6 (0, 1, 10, 100 μg/mL or 38.46 nmol/L, 384.6 nmol/L, and 3.85 μmol/L), IL-1α (55.5 μmol/L, 555.5 μmol/L, and 5.5 mmol/L) and IL-1β (57.1 μmol/L, 571.4 μmol/L, and 5.7 mmol/L). ECFC colony formations were enumerated every other day for 2 weeks. The assay was performed in triplicate. The maximum numbers of colonies per well were used for analyses. In 3 separate sets of experiments, BM ECFC colonies were treated in triplicate with 1 μg/mL of IL-6 and then given 1 μg/mL of IL-6RA; 1 μg/mL of each of IL-1α and IL-1β and then given 1, 0.1, and 0.5 ng/mL of IL-1RA. 17 Cytokine concentrations and antagonist concentrations were chosen based on available previous reports. 18 Colony formations were enumerated daily for 2 weeks, in a manner identical to that described above, and the maximal numbers of colonies per well were used for analyses.
Statistical Analyses
Because cytokines have lower and upper limits of detectability, rank methods were used for ordinal associations between cytokines and outcomes of interest (ie, clinical and laboratory data). Spearman rank correlation coefficients were calculated to evaluate associations between the level of cytokines in the PB and colony counts for both BM and PB. Spearman rank correlation coefficients were also calculated for determining associations between PB cytokine levels and cardiac function tests (echocardiogram and cardiac magnetic resonance imaging). Wilcoxon signed-rank tests were used to determine associations with binary demographic variables.
Multivariable regression analysis was used to evaluate associations between all angiogenesis, proinflammatory cytokines, antiinflammatory cytokines, and colony assays. To confirm our results, using a different approach, we selected the significant cytokines (P≤0.2) in correlation with a colony-forming cell assay and then ran the multiple regression model between the selected cytokines and each colony-forming cell. In addition, sensitivity analyses 19, 20 were conducted to test our primary multivariable method with 3 possible approaches to manage cytokine concentrations that were below the lower LOD, based on the kit validation. For the first sensitivity analysis, we used the actual LOD; for the second sensitivity analysis, we used half of LOD; and for the third sensitivity analysis, we used a random number between 0 and the LOD for study participants whose values were below the LOD. To compare colony counts after treating BM-mononuclear cell with IL-6 in our experimental study, nonparametric tests were used to calculate the statistical significance of differences between 2 groups of paired data (Wilcoxon signed-rank test). The level of statistical significance was set at P<0.05 to detect any significant associations. Data were analyzed using SAS 9.3. No error controls were used for this study, as false negatives are at least as serious as false positives when screening for promising research leads. This report selectively details the significant associations.
Results
Patient Characteristics
The complete details about patient characteristics in the LateTIME trial have been reported. 3, 16 In brief, mean age was 57 years, 83% were men, 86% were white, mean body mass index was 27.8 kg/m 2 , and there were high proportions of study participants with cardiac risk factors including smoking (59%), hypertension (53%), and hyperlipidemia (70%).
Cytokine Levels in PB After AMI
PB cytokine concentrations from participants with AMI are summarized in Table 1 and juxtaposed to previously reported cytokine concentrations from healthy individuals. Of note, the median concentrations of inflammatory cytokines known to impair the regenerative capacity of BM after AMI were 11.2 pg/mL for IL-6, 1.4 pg/mL for IL-1α, and 3.2 pg/mL for IL-1β. Among the cytokines, IL-1α, IL-1β, interferon-γ, IL-4, and IL-5 had the highest number of concentrations below the lower LOD. IL-1α had 73 (83.9%), interferon-γ had 70 (80.4%), IL-1β had 69 (79.3%), IL-4 had 60 (68.97%), and IL-5 had 62 (71.26%) participants whose values were below the LOD.
Angiogenic Cytokines Associated With BM or PB Cell Function After AMI
Multiple regression models were used to assess correlations between angiogenic or arteriogenic cytokines (basic fibroblast growth factor, PDGF-BB, vascular endothelial growth factor, and stromal cell-derived factor-1α) and BM or PB progenitor cell colony capacities. Among angiogenic cytokines, only PDGF-BB positively correlated with BM-derived colonyforming unit-endothelial colony number (estimate±SE [ (Table 2 ). Sensitivity analyses confirmed the significant positive associations between PB PDGF-BB concentration and BM-derived colony-forming unit-endothelial colony number, BM-derived MSC colony number and PB-derived MSC colony number. To confirm our finding, in a second approach, we selected the significant angiogenic cytokines in correlation with colony-forming assays and ran the multiple regression models between the selected cytokines and each of the colonyforming assays, separately. This second approach confirmed the significant positive association of PDGF-BB with MSC colony maximum from BM (ESE, −0.01±0.002; P=0.02).
Proinflammatory Cytokines Associated With BMC Function After AMI
Multiple regression analysis was used to model the relationship between proinflammatory cytokines (eotaxin, granulocyte CSF, granulocyte-macrophage CSF, interferon-γ, IL-12, IL-15, IL-17a, IL-1β, IL-1α, IL-2, IL-6, IL-7, IL-8, IL-9, tumor necrosis factor-α, monocyte chemoattractant protein-1, and chemokine (C-C motif) ligand 5) with each of the endothelial and mesenchymal cell assays. Participants with higher IL-6 after AMI showed larger reductions in endothelial progenitor cell capacity in BM (ECFC colony number) (ESE, −0.13±0.05; P=0. 007; multivariable R 2 , 0.60). In addition, IL-12p70 was negatively associated with ECFC colony of BM (ESE, −0.01±0.007; P=0. 050; multivariable R 2 , 0.60; Table  3 ). Moreover, after adjusting for age, sex, body mass index, history of smoking, and the time of BM cell therapy after AMI, participants with higher IL-6 had larger reductions of ECFC colony count in BM (ESE, −0.15±0.02; P<0.001; multivariable R 2 , 0.60). Sensitivity analyses confirmed that IL-6 was negatively associated with endothelial progenitor cell capacity in BM. Again, to confirm results, we used a second approach that selected the significant inflammatory cytokines in correlation with colony-forming assays and ran the multiple regression models between the selected cytokines and endothelial assay. The second approach confirmed the significant negative association of IL-6 with ECFC colony maximum from BM (ESE, −0.13±0.04; P=0.003; standardized coefficient, −3.1). AMI indicates acute myocardial infarction; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-γ; IL, interleukin; LOD, limit of detection; MCP-1, monocyte chemoattractant protein-1; N/A, not available; PDGF-BB, platelet-derived growth factor BB glycoprotein; RANTES, chemokine (C-C motif) ligand 5; SDF-1, stromal cell-derived factor 1; VEGF, vascular endothelial growth factor; and TNF-α, tumor necrosis factor-α.
*No result was obtained for 8 of 2436 samples tested and these missing values randomly distributed across the list of measured cytokines.
†Personal communication from Giulio Kleiner on behalf of Dinarello.
Association of Cytokines and Baseline Cardiac Function
Per LateTIME trial protocol, baseline cardiac functions were measured on the same day of PB collection. Cardiac function measurements included LVEF, LV end-diastolic volume (LVEDV), and LV end-systolic volume. We examined the extent that each PB cytokine correlated with baseline cardiac function measure. We found that the level of IL-9 negatively correlated with LVEF and positively correlated with LVEDV (Table 4) , suggesting an association between the proinflammatory cytokine IL-9 and worse cardiac function. Other cytokines, such as granulocyte-macrophage CSF, granulocyte CSF, and IL-17a positively associated with cardiac function measures. There was no significant association between IL-6 and cardiac function (Table 4) .
Focused Analysis on IL-6 and Cardiac Function Improvement
Given that IL-6 was negatively associated with BM colony outgrowth impairment after AMI, we hypothesized that higher IL-6 level may correlate with reduced improvement in cardiac function after BMC or placebo therapy. Therefore, a focused analysis was performed to compare cardiac function at 6-month follow-up in the subsets of participants with high IL-6 and high IL- Figure 1 ).
Focused Analysis on IL-6 and IL-10 on BM or PB Cell Function After AMI
A previous study of patients with ST-segment-elevation myocardial infarction (STEMI) showed that simultaneous elevation of IL-6 and IL-10 levels identified patients with poor clinical outcomes. 23 Our study extends the importance of IL-6 and IL-10 on BM impairment after AMI. Therefore, we examined the ratio of IL6/IL-10 in addition to IL-6 and IL-10 alone. Univariate analysis of the individual IL-6 and IL-10 concentrations detected no significant associations with BM and PB cell function. However, multivariable analysis of IL-10, IL-6, and IL-6/IL-10 ratio with each of BM or PB colony numbers showed that IL-6 negatively associated with MSC colony number maximum from PB (standard coefficient −2.4; P=0.01) and IL-10 positively associated with MSC colony numbers from PB (standard coefficient 3.4; P=0.001; R 2 =0.2; Table 5 ).
Reversal of IL-6 Impairment of BM-Derived Endothelial Progenitor Colony Formation
Having observed that IL-6 levels correlated with reduced BM endovascular colony outgrowth in patients with AMI, we next sought to confirm the associative findings. To this end, BM samples from 3 healthy individuals were cultured in ECFC CFU-EC indicates colony-forming unit-endothelial colony; FGF, fibroblast growth factors; MSC, mesenchymal stromal cell; PDGF-BB, platelet-derived growth factor BB glycoprotein; SDF-1α, stromal cell-derived factor 1α; and VEGF; vascular endothelial growth factor. assay and treated with increasing concentrations of IL-6. ECFC colony numbers were enumerated every other day for 14 days. BM in control conditions generated ECFC colonies as expected (Figure 2A) . However, when cultures were exposed to IL-6, the number of ECFC colonies decreased in a dose-dependent fashion ( Figure 2C ). ECFC colony counts were significantly decreased after exposure to 1 μg/mL of IL-6 (mean±SE, 7.42±1.17; P=0.014), 10 μg/mL of IL-6 (mean±SE, 5.71±1.18; P=0.002), and 100 μg/mL of IL-6 (mean±SE, 2.28±1.60; P=0.001) in comparison with the healthy reference group (mean±SE, 11.42±1.97; Figure 2C ). These results support the finding that IL-6 exerted an inhibitory action on BM-derived endothelial progenitor cell colony outgrowth in patients with AMI.
We next investigated whether the inhibitory effects of IL-6 on the BM could be reversed. We added an IL-6RA to BM ECFC cultures that were spiked with IL-6. Again, in conditions with no IL-6Ra, IL-6 reduced the number of BM ECFC colonies compared with untreated controls ( Figure 2D) . However, the addition of 1 μg/mL of IL-6Ra resulted in increased BM ECFC colonies compared with BM treated with 1 μg/mL of IL-6 and no IL-6Ra (mean±SE, 7±0.2 versus 5.8±1.49; P=0.003; Figure 2D ). These results support the notion that IL-6Ra can rescue BM that has been compromised by IL-6, although the reversal was partial.
IL-1 Receptor Antagonism Improves BM-Derived Endothelial Progenitor Colony Formation
Given IL-6 signaling downstream of IL-1 receptor and the known sequential appearance of IL-1β and IL-6 after AMI, we next sought to examine the effects of IL-1α/β on BMderived vasculogenic colony outgrowth. We observed that BM-mononuclear cell colony formation was significantly decreased after exposure to either IL-1α or IL-1β in a dosedependent manner. ECFC colony counts, after treating with 1 μg of IL-1α (8.71±5.5 mean±SE; P=0.01) or 1 μg of IL-1β (6±4; P<0.001), were significantly lower compared with the healthy control group without exposure to the cytokine (mean, 11.42±1.97; Figure 3A and 3B).
We next examined whether inhibition of IL-1R could improve the ECFC colony outgrowth. We treated the BMmononuclear cells, separately with either IL-1α or IL-1β in a control group and compared the colony formation after the addition of incrementally increasing doses of IL-1R antagonist (IL-Ra). We observed that the ECFC colony outgrowth significantly improved with IL-1RA compared with the control group ( Figure 3C and 3D ).
Discussion
In this study, we report the levels of circulating angiogenic and inflammatory cytokines in patients 2 to 3 weeks after AMI. We found that patients with increased PB levels of the angiogenic cytokine PDGF-BB exhibited increased BMderived endothelial and mesenchymal colony outgrowth. In contrast, AMI participants with increased PB levels of the inflammatory cytokine, IL-6, showed decreased BM-derived endothelial progenitor cell outgrowth. These results support our hypothesis that cytokine signaling after AMI alters BM phenotype and function, a phenomenon that may underlie the mixed clinical response to autologous BMC after AMI. After AMI, dying cardiomyocytes trigger a systemic inflammatory response through the activation of the nuclear factor-κB pathway, which induces release of many proinflammatory cytokines such as IL-1β, IL-6, and tumor necrosis factor-α. 24 The sequential appearance of IL-1β and IL-6 is known to initiate and regulate the inflammatory response after AMI. [25] [26] [27] Our results indicate that participants with higher IL-6 after AMI show larger reductions in endothelial progenitor cell capacity in BM. Moreover, our experimental study supported a role of IL-6 in the impairment of BM-derived vasculogenic capacity. Although our results are consistent with an important function of IL-6 late after AMI in impairment of autologous BM, we found that IL-1α and IL-1β levels in the PB were low. Given that previous rat studies have shown higher levels of circulating cytokines early (hours-to-days) after AMI compared with late (weeks) after AMI, 28 it is possible that IL-1α and IL-1β levels in patients may be higher at earlier time points (days) after AMI and then abate later (weeks). Serial measurements of PB cytokines in humans beginning early after AMI will be necessary to examine this possibility.
In a previous observational study of ST segment elevated AMI patients, the combined analysis of the circulating proinflammatory cytokine, IL-6, and the circulating anti-inflammatory cytokine, IL-10, identified high-risk patients with worse clinical outcomes. 23 Patients with high IL-6 and high IL-10 in PB had an increased risk of LV systolic dysfunction at hospital discharge and an increased risk of death at 6 months. This study confirms and extends the importance of IL-6 as a potential prognostic risk factor and potential target for reversing BM impairment after AMI.
Although no significant associations were found between IL-6 with baseline ejection fraction or IL-6 with ejection fraction after cell therapy, the concept that IL-6 as a proinflammatory cytokine may be associated with greater reduction in regenerative capacity of BM is worthy of further study. Another important consideration is the appropriateness of ejection fraction as an outcome of interest. It is possible that LVEF, LV end-systolic volume, and LVEDV are not appropriate outcome measurements. Other measures of cardiac function such as left ventricular global function index, 29 return of functional capacity, cardiac symptoms, and MACE (major adverse cardiac event) events might be more helpful in defining significant correlations between cytokines and cardiac function. BMC therapy after AMI has shown minimal to no improvement in left ventricular function after reperfusion. 5 There is much controversy about autologous BMC therapy with different CFU-EC indicates colony-forming unit-endothelial colony; ECFC, endothelial colony-forming cell; IL, interleukin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; and MSC, mesenchymal stromal cell.
views. Preclinical studies indicate that locally delivered BMCs can regenerate de novo myocardium. 30 Furthermore, parabiosis experiments suggest that stem/progenitor cell regeneration of the infarcted myocardium may occur in the early time period after intramyocardial injection; however, over time, most of the regenerated cells either die or migrate elsewhere. 31 In a recent cell therapy experiment, 14 cytokines released from the infarcted myocardium were implicated as impairing the regenerative potential of BMCs. Thus, the cardiovascular cell therapy community has struggled to reconcile experimental results with clinical trial experience. In this study, we sought reasons for the lack of cardiac function improvement after autologous BMC therapy and used LateTIME data for this exploration. Results of this study support the concept that inflammatory cytokines released after AMI impair the reparative ability of the BM, which may explain the lack of efficacy seen in autologous BMC therapy studies. Our data suggest that PDGF-BB may be a biomarker for positive response to cell therapy and IL-6 may be a key offender 2 weeks after AMI.
However, we also found that blocking IL-6 or IL-1 receptors using an IL-6RA or IL-1RA in vitro mitigated the inflammatory cytokines' repressive effects on BM. These findings may be clinically relevant because inhibitors to these cytokines are already Food and Drug Administration approved and could be applied after AMI with the intent of improving the regenerative capacity of autologous BMCs.
Previous experimental studies of IL-6R inhibition in rodent models of AMI have generated mixed results. Whereas a first study of IL-6R inhibition in AMI showed suppression of myocardial inflammation, improvement in LV function and lengthened survival time, a follow-up study showed worsened LV function but no histological changes after IL-6R inhibition. 32, 33 There were significant methodological differences between the 2 preclinical studies, with the first using single dose of IL-6R antibodies in a mouse coronary ligation model assessed by echocardiography and the second using repeated dosing of IL-6R antibodies in an ischemia-reperfusion mouse model assessed by cardiac nuclear magnetic resonance imaging. Common to both studies were reductions in inflammatory cytokines after AMI. However, it is possible that a single dose of IL-6R-antagonist after AMI neutralized the acute increase of IL-6 and prevented LV remodeling, whereas prolonged IL-6R-antagonism not only neutralized IL-6 in the acute setting but also prevented wound healing in later phases after AMI. In clinical translation, a recent phase I clinical trial of a single dose of IL-6RA, tocilizumab, before coronary angiography in patients with non-STEMI suppressed the levels of PCI-related inflammatory biomarkers after AMI and secondarily reduced troponin release. 34 This early phase clinical trial demonstrated the feasibility of single-dose IL-6R antagonism in patients with AMI. It is noted that this study was not designed to examine efficacy but serves as the basis for designing and executing such phase II and III clinical trials of IL-6R antagonism in patients with AMI.
The cytokine IL-1β is best known for its role in inflammation, but it also participates in a host of other physiological processes including the regulation of BM hematopoietic stem and progenitor cells, which express IL-1R. 22 IL-1β mobilizes hematopoietic stem and progenitor cells from the BM by enhancing transendothelial migration between or through BM endothelial cells. 35 IL-1β also induces IL-6 secretion, stimulates prostaglandin production, alters hematopoietic stem and progenitor cell differentiation and at certain doses can impair hematopoietic stem and progenitor cell colony outgrowth and self-renewal. 36 Results from this report extend previous findings by showing that IL-1β impairs BM-derived vasculogenic activity. We also demonstrate that this impairment can be mitigated by IL-1RA. Already, investigators have attempted to block IL-1 in patients with cardiovascular diseases. A placebo-controlled, randomized study of the recombinant IL-1RA, anakinra, in 30 patients with STEMI showed that anakinra significantly reduced circulating C-reactive protein levels and reduced the proportion of patients with STEMI who developed heart failure. 37, 38 Another placebo-controlled, randomized phase II clinical trial of anakinra in patients with non-STEMI AMI showed significant reduction in circulating C-reactive protein levels. 39 Although this previous study was not powered to assess clinical outcomes, there was an increase in the MACE composite for the anakinra-treated group, primarily driven by recurrent myocardial infarction (MI). In both anakinra studies, the treatment dose (100 mg/d) and duration (14 days) clearly blunted the acute inflammatory reaction after MI. Yet to be determined is whether a shorter course of IL-1 blockade adequately diminishes deleterious immune reactivity after AMI while avoiding late adverse effects. Another strategy of blocking IL-1 activity is via a soluble decoy receptor, rilonacept, which binds and neutralizes IL-1β, IL-1α, and IL-1RA. This drug is Food and Drug Administration approved for use in patients with IL-1β-driven inflammatory disorders such as cryopyrin-associated periodic syndrome, including the NLRP3-mutant diseases of familial cold autoinflammatory syndrome and Muckle-Wells syndrome. In an experimental model of AMI, mice treated with a murine IL-1 decoy receptor (IL-1 Trap) had more favorable cardiac remodeling and reduced infarct sizes than saline-control animals. 40 There are no published studies about the effect of rilonacept in patients with cardiovascular disease. Another strategy for IL-1 blockade uses the monoclonal antihuman IL-1β antibodies, canakinumab, which is approved for the use in patients with cryopyrin-associated periodic syndrome. Canakinumab is currently being investigated in a large, multinational, placebo-controlled, randomized clinical trial involving patients with AMI and persistent elevation of high-sensitivity C-reactive protein levels (CANTOS trial [Canakinumab Anti-inflammatory Thrombosis Outcomes Study], NCT01327846). 41 With specific regard to cardiovascular cell therapy trial design, it is envisioned that harvested autologous BMCs would be incubated -1β (1, 10 , or 100 μg/mL). Colony formations enumerated for 2 weeks, and the maximal number of colonies per plate was used for analyses. EFCF colony counts significantly decreased after exposure to IL-1α or IL-1β in a dosedependent manner. Colony numbers of healthy BM-MNCs treated with 1 μg/ mL of IL-1α (C) or 1 μg/mL of IL-1β (D) as a control group were compared with ECFC colony counts after exposing to increasing concentrations of IL-1RA (0.1, 0.5, and 1 ng/mL). ECFC colony outgrowth improved significantly after treating with IL-1RA. *P<0.05.
ex vivo with lower dose and shorter exposure time to the cytokine RA before administration back to the patient.
When interpreting our results, a few considerations are required. First, the timing of cytokine sampling in this study was 2 to 3 weeks after AMI. At this time point, acute phase reactants have waned. Thus, the important biology that we present in this report is only part of the post-MI picture. Second, our in vitro experiments with IL-6 and IL-1β contained higher concentrations compared with the cytokine concentrations detected in patient PB 2 to 3 weeks after AMI. The primary intent of the laboratory experiments was to establish a proof of concept whether IL-6 or IL-1β reduced, increased or had no effect on BM-derived colony outgrowth. Agnostic to the effects, our results are clearly consistent with a dose-dependent impairments of BM colony capacity. One major caveat is that our experiments were not designed to define absolute cytokine concentrations relative to BM function. Local concentrations of IL-6 and IL-1α/β after MI in either cardiac tissue or BM are unknown and were not sampled in this study. Furthermore, because our PB sampling was in the subacute phase after MI, we may have missed the peak PB concentrations of IL-6 and IL-1β. Although our results support the overarching concept of IL-6 or IL-1β cytokine impairment of autologous BMCs after AMI, any extrapolation from culture dish to human application would be fraught with assumptions and deserving of designed for biological scaling.
Limitations
This study examined baseline cytokine levels from patients recruited to the LateTIME study. The clinical trial was not designed nor powered to define absolute cytokine levels or determine exact dose and schedule of cytokine RAs. Results from this study are proof of concept and not intended to direct therapeutic decision-making. In addition, several PB cytokines were at concentrations below the limit of assay detection. Given these low concentrations and to further appraise our multiple regression analysis strategy, we conducted sensitivity analyses at 3 levels, which confirmed the significant association of IL-6 and BM-derived vasculogenic colony outgrowth.
Conclusions
Two to three weeks after AMI, circulating cytokine concentrations associated with BM function and response to autologous BMC therapy. PDGF-BB positively correlated with BM-derived endovascular clonogenic capacity. IL-6 and IL-1β adversely affected BM colony outgrowth, which may have contributed to the lack of efficacy seen in autologous BMC therapy studies. Blocking the IL-6 receptor or IL-1 receptor restored BM endovascular function, suggesting a potential new therapeutic strategy for restoring autologous BM function after AMI.
